LeMaitre Vascular, Inc.

LeMaitre Vascular, Inc.

LMATNYSE / NASDAQHealthcareMid cap

$73.61-$1.25 (-1.7%)

Last close · Data as of Nov 20, 2026

Market cap
$2.1B
P/E
37.0x
EV / EBITDA
25.3x
Revenue
$249.6M
Net margin
23.1%
ROCE
11.7%

-12.8% over the last year

LeMaitre Vascular, Inc. price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 20 Nov 2026 close.

1M
-11.7%
3M
-10.6%
6M
-27.4%
1Y
-12.8%
5Y
+41.9%

52-week range

Day change -$1.25 (-1.7%) from $75 to $74 · Last close Nov 20, 2026

Best weekday to invest, historically

The same weekly amount in LMAT, bought on each weekday since 2021.

News & filings

What LeMaitre Vascular filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

ConcernThe P/E of 37.0 is more than four times the peer median of 4.7.

Strengths (1)

  • Current assets are more than ten times current liabilities.

Prices to the 20 Nov 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

LeMaitre Vascular, Inc. develops, manufactures, and markets medical devices and implants used in the field of vascular surgery in the Americas, Europe, the Middle Esat, Africa, and the Asia Pacific.

Read moreShow less

LeMaitre Vascular, Inc. develops, manufactures, and markets medical devices and implants used in the field of vascular surgery in the Americas, Europe, the Middle Esat, Africa, and the Asia Pacific. The company offers allografts, which are cryopreserved human tissue grafts used in vascular reconstruction, and cardiac repair and reconstruction; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature, as well as human cadaver tissue cryopreservation services. It provides a suite of biologic products comprising artegraft biologic graft, a bovine carotid artery used for dialysis access; XenoSure biologic patches used for vessel closure after surgical intervention; VascuCel and CardioCel biologic patches, used in vessel repair, heart repair and reconstruction, and neonatal repairs; carotid shunts that temporarily shunt the blood to the brain; biosynthetic vascular grafts indicated for lower extremity bypass and dialysis access; phlebectomy system for resection and ablation of varicose veins; LifeSpan vascular grafts, which are expanded polytetrafluoroethylene grafts; and vascular grafts used to bypass or replace diseased arteries. In addition, the company offers radiopaque tape, a medical-grade tape; valvulotomes, which cut or disrupt valves in the saphenous vein to function as an artery to carry blood past diseased arteries to the lower leg or the foot; and closure systems to attach vessels to one another with titanium clips instead of sutures. It markets its products through a direct sales force and distributors. The company was formerly known as Vascutech, Inc. and changed its name to LeMaitre Vascular, Inc. in April 2001. LeMaitre Vascular, Inc. was incorporated in 1983 and is headquartered in Burlington, Massachusetts.

Sector
Healthcare
Shares outstanding
22.6M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$2.1B
P/E
37.0x
P/B
5.4x
EV / EBITDA
25.3x
EV / Sales
9.2x
P/S
8.6x
52-week high
$117.39
52-week low
$73.61

Profitability

Operating margin
27.2%
Net margin
23.1%
EBITDA margin
36.4%
ROE
14.7%
ROCE
11.7%
ROA
9.4%
Asset turnover
0.41

Growth

Revenue
$249.6M
Revenue growth, 1Y
13.5%
Revenue CAGR, 3Y
15.6%
Net profit growth, 1Y
31.1%
Free cash flow
$74.5M

Solvency

Current ratio
12.89
Debt / Equity
0.47
Debt / Assets
0.30
CFO / Net profit
1.41
Cash / Market cap
1.3%

Where the revenue went

Of every $100 of FY2025 revenue, $23 was left as net income.

LeMaitre Vascular, Inc. income statement flow, FY2025
LeMaitre Vascular, Inc. income statement flow, FY2025: flows
FromToAmount
RevenueCost of revenue$71.1M
RevenueGross profit$178.5M
Gross profitResearch and development$14.1M
Gross profitSelling, general and administrative$96.5M
Gross profitOperating income$67.9M
Operating incomePretax income$67.9M
Interest and other incomePretax income$7.3M
Pretax incomeTax and other$17.5M
Pretax incomeNet income$57.7M

Revenue and net profit

Revenue grew 13.5% in FY2025; net profit is the dashed line.

LeMaitre Vascular, Inc. revenue and net profit by fiscal year
LeMaitre Vascular, Inc. revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$161.7M$20.6M
FY2023$193.5M$30.1M
FY2024$219.9M$44.0M
FY2025$249.6M$57.7M

Cash flows

FY2025: $81.3M from operations, $74.5M free after investment (dashed).

LeMaitre Vascular, Inc. operating and free cash flow by fiscal year
LeMaitre Vascular, Inc. operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022$25.4M$22.1M
FY2023$36.8M$29.5M
FY2024$44.1M$37.2M
FY2025$81.3M$74.5M

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$249.6M+13.5%1Y
EBITDA
$90.8M+36.1%1Y
Net profit
$57.7M+31.1%1Y
Cash from operations
$81.3M+84.1%1Y
Free cash flow
$74.5M+100.4%1Y
Revenue CAGR, 3Y
15.6%
Net profit CAGR, 3Y
40.9%
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$249.6M$90.8M$57.7M$74.5M14.7%+13.5%+31.1%

Monthly returns

Month-by-month returns of LMAT across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$615.7M
Liabilities$222.2M
Equity$393.5M
Paid-in capital$228.4M
Retained earnings$184.7M
Treasury stock$17.4M

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Healthcare companies placed by value, growth and quality; LMAT highlighted.

P/E against peers

LMAT trades at 37.0x earnings against a peer median of 4.7x (a 680% premium).

Not shown (no positive earnings and no EV / Sales): Supernus Pharmaceuticals, Inc., Acadia Healthcare Company, Inc., Neogen Corporation, Sarepta Therapeutics, Inc.

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
LeMaitre Vascular, Inc.LMATthis companyP/E ↑ premium$2.1B37.0x5.4x14.7%25.3x
Supernus Pharmaceuticals, Inc.SUPN$2.6B-67.3x2.4x-3.6%58.9x
TransMedics Group, Inc.TMDX$2.5B13.0x5.2x40.2%16.8x
Acadia Healthcare Company, Inc.ACHC$2.3B-2.1x1.2x-56.6%-6.5x
Prestige Consumer Healthcare Inc.PBH$2.2B11.3x1.1x10.1%9.5x
Select Medical Holdings CorporationSEM$2.0B14.0x1.2x8.6%9.2x
Neogen CorporationNEOG$2.0B-1.8x1.0x-52.7%-2.9x
ADMA Biologics, Inc.ADMA$1.8B12.6x3.9x30.8%9.3x
Sarepta Therapeutics, Inc.SRPT$1.8B-2.5x1.5x-62.5%-3.2x
Peer median—4.7x1.4x2.5%9.3x

Year-to-date ROI

LMAT since 1 January, against earlier years.

Historical volatility

LMAT's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

Operating margin by fiscal year

LeMaitre Vascular, Inc. operating margin by fiscal year
LeMaitre Vascular, Inc. operating margin by fiscal year
DateOperating margin
FY202218.5%
FY202319.2%
FY202423.8%
FY202527.2%
LineFY2025
Cost of revenueCost Of Revenue$71.1M
Gross profitGross Profit$178.5M
Operating expensesOperating Expense$110.6M
Research and developmentResearch And Development$14.1M
Total expensesTotal Expenses$181.7M
Pretax incomePretax Income$75.2M

Learn while you research

Academy chapters picked for LeMaitre Vascular, Inc. and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Valuation Multiples ExplainedThis stock trades at a P/E of 37.0, learn when high multiples are justified.6 min read
  3. 03 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  4. 04 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
  5. 05 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read
Browse the full Equiscale Academy →